The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,001
Dąbrowski, M. J., & Wojtaś, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143478 · Cited by 73
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
Mitochondrial determinants of cancer health disparities
Choudhury, A. R., & Singh, K. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.001 · Cited by 75
Zhou, L., Wang, Z., Hu, C., Zhang, C., Kovatcheva‐Datchary, P., Yu, D., Liu, S., Ren, F., Wang, X., Li, Y., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00663 · Cited by 73
Nakagawa, M., Nakatani, F., Matsunaga, H., Seki, T., Endo, M., Ogawara, Y., Machida, Y., Katsumoto, T., Yamagata, K., Hattori, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0929-9 · Cited by 78
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 75
Oxidative stress-mediated alterations in histone post-translational modifications
García‐Giménez, J. L., Garcés, C., Mateo, C. R., & Pallardó, F. V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.027 · Cited by 75
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Stubbins, R. J., & Karsan, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00584-3 · Cited by 75
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, C., Drucker, K. L., Kollmeyer, T. M., Tsai, R., Winick‐Ng, W., Liang, M., Malik, A., Pawling, J., Lorenzo, S. B. D., Ali, A., et al. (2022) · Science · doi:10.1126/science.abj2890 · Cited by 77
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 75
Mitochondrial Citrate Transporter-dependent Metabolic Signature in the 22q11.2 Deletion Syndrome
Napoli, E., Tassone, F., Wong, S., Angkustsiri, K., Simon, T. J., Song, G., & Giulivi, C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672360 · Cited by 71
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Self-citationMitochondrial dependency in progression of acute myeloid leukemia
Basak, N. P., & Banerjee, S. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.01.006 · Cited by 75
Tumor Metabolism of Malignant Gliomas
Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 73
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 73
The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
Han, C., Zheng, J., Sun, L., Yang, H., Cao, Z., Zhang, X., Zheng, L. T., & Zhen, X.-C. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0225-9 · Cited by 75
Xu, H., Sun, Y., You, B., Huang, C., Ye, D., & Chang, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.014 · Cited by 72
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity
Cavalli, G., Tengesdal, I. W., Gresnigt, M. S., Nemkov, T. G., Arts, R. J. W., Domínguez‐Andrés, J., Molteni, R., Stefanoni, D., Cantoni, E., Cassina, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108955 · Cited by 74
A Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks
Nam, H., Campodonico, M. A., Bordbar, A., Hyduke, D. R., Kim, S., Zielinski, D. C., & Palsson, B. Ø. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003837 · Cited by 71
Investigational cancer drugs targeting cell metabolism in clinical development
Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72
Kurek, K. C., Pansuriya, T. C., van Ruler, M. A. J. H., van den Akker, B., Luks, V. L., Verbeke, S., Kozakewich, H. P., Sciot, R., Lev, D. C., Lazar, A. J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.012 · Cited by 73
Cancer stem cells: a potential target for cancer therapy
Qiu, H. Y., Fang, X., Luo, Q., & Ouyang, G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1920-4 · Cited by 72
The lncRNA Connection Between Cellular Metabolism and Epigenetics in Trained Immunity
Fok, E. T., Davignon, L., Fanucchi, S., & Mhlanga, M. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03184 · Cited by 76
Bernstock, J. D., Mooney, J. H., Ilyas, A., Chagoya, G., Estévez-Ordoñez, D., Ibrahim, A. G. A., & Nakano, I. (2019) · Journal of neurosurgery · doi:10.3171/2019.5.jns19364 · Cited by 75
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 71
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 73
Acetoacetate Accelerates Muscle Regeneration and Ameliorates Muscular Dystrophy in Mice
Zou, X., Meng, J., Li, L., Han, W., Li, C., Zhong, R., Miao, X., Cai, J. C., Zhang, Y., & Zhu, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.676510 · Cited by 70
Cleven, A. H. G., Suijker, J., Agrogiannis, G., Bruijn, I. H. B., Frizzell, N., Hoekstra, A. S., Wijers‐Koster, P. M., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0074-6 · Cited by 72
Metabolic signatures of human breast cancer
Mishra, P., & Ambs, S. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.992217 · Cited by 70
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71
Jin, Y., Elalaf, H., Watanabe, M., Tamaki, S., Hineno, S., Matsunaga, K., Woltjen, K., Kobayashi, Y., Nagata, S., Ikeya, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131998 · Cited by 70
Deletion of the Mitochondrial Chaperone TRAP-1 Uncovers Global Reprogramming of Metabolic Networks
Lisanti, S., Tavecchio, M., Chae, Y. C., Liu, Q., Brice, A. K., Thakur, M. L., Languino, L. R., & Altieri, D. C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.061 · Cited by 69
DNA methylation processes in atherosclerotic plaque
Aavik, E., Babu, M., & Ylä‐Herttuala, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.006 · Cited by 72
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
Chen, Y., Fang, R., Yue, C., Chang, G., Li, P., Guo, Q., Wang, J., Zhou, A., Zhang, S., Fuller, G. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1229 · Cited by 69
Zeng, W., Yang, Y., Liu, Z.-Z., Wen, Z., Chen, Y., Hu, X., Cheng, Q., Xiao, J., Zhao, J., & Chen, X. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489954 · Cited by 69
Glioblastoma multiforme: novel therapeutic targets
Muir, M. T., Gopakumar, S., Traylor, J. I., Lee, S., & Rao, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762568 · Cited by 71
Fanelli, G. N., Grassini, D., Ortenzi, V., Pasqualetti, F., Montemurro, N., Perrini, P., Naccarato, A. G., & Scatena, C. (2021) · Genes · doi:10.3390/genes12030445 · Cited by 72
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.008 · Cited by 69
IDH1: Linking Metabolism and Epigenetics
Raineri, S., & Mellor, J. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00493 · Cited by 70
Dong, W., Keibler, M. A., & Stephanopoulos, G. N. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.02.002 · Cited by 69
Miller, J. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01238-3 · Cited by 70
Metabolic Regulation of Hematopoietic Stem Cells
Morganti, C., Cabezas‐Wallscheid, N., & Ito, K. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000740 · Cited by 82
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 68
Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions
Kim, T. K., Gore, S. D., & Zeidan, A. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.04.003 · Cited by 67
A global assessment of cancer genomic alterations in epigenetic mechanisms
Shah, M. A., Denton, E., Arrowsmith, C. H., Lupien, M., & Schapira, M. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-29 · Cited by 71
Alsadoun, N., MacGrogan, G. M., Truntzer, C., Lacroix‐Triki, M., Bedgedjian, I., Koeb, M.-H., Alam, E. E., Médioni, D., Parent, M., Wuithier, P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0047-1 · Cited by 69
Duchmann, M., Micol, J., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J., Braun, T., Adès, L., Chantepie, S., Lemasle, É., et al. (2021) · Blood · doi:10.1182/blood.2020010165 · Cited by 66
Natsumeda, M., Igarashi, H., Nomura, T., Ogura, R., Tsukamoto, Y., Kobayashi, T., Aoki, H., Okamoto, K., Kakita, A., Takahashi, H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0158-y · Cited by 64
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 69
Clinical implications of molecular markers in acute myeloid leukemia
Käyser, S., & Levis, M. J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13172 · Cited by 70
Treatment of Glioblastoma in Older Adults
Braun, K. E., & Ahluwalia, M. S. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0644-z · Cited by 64
Characteristics and prognostic impact ofIDHmutations in AML: a COG, SWOG, and ECOG analysis
Zarnegar‐Lumley, S., Alonzo, T. A., Gerbing, R. B., Othus, M. K. D., Sun, Z., Ries, R. E., Wang, J., Leonti, A. R., Kutny, M. A., Ostronoff, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008282 · Cited by 70
Self-citationBaxevanis, C. N., & Perez, S. A. (2015) · Vaccines · doi:10.3390/vaccines3030597 · Cited by 68
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 63
Leather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 65
Mitochondrial Metabolism in Major Neurological Diseases
Zhou, Z., Austin, G. L., Young, L. E. A., Johnson, L. A., & Sun, R. C. (2018) · Cells · doi:10.3390/cells7120229 · Cited by 67
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
Court, F., & Arnaúd, P. (2016) · Oncotarget · doi:10.18632/oncotarget.13746 · Cited by 61
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.007 · Cited by 65
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., & Illig, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11759 · Cited by 64
Tran, T. Q., Gabra, M. B. I., Lowman, X. H., Yang, Y., Reid, M. A., Pan, M., O'Connor, T. R., & Kong, M. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2002810 · Cited by 65
Laukka, T., Myllykoski, M., Looper, R., & Koivunen, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.048 · Cited by 69
Recent advances in the understanding and treatment of acute myeloid leukemia
Watts, J. M., & Nimer, S. D. (2018) · F1000Research · doi:10.12688/f1000research.14116.1 · Cited by 61
Riobello, C., López‐Hernández, A., Cabal, V. N., García‐Marín, R., Suárez–Fernández, L., Sánchez‐Fernández, P., Vivanco, B., Blanco, V., López, F., Franchi, A., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001420 · Cited by 61
Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
Mirchia, K., & Richardson, T. E. (2020) · Cancers · doi:10.3390/cancers12071817 · Cited by 64
Griffioen, M. S., de Leeuw, D. D., Janssen, J., & Smit, L. (2022) · Cancers · doi:10.3390/cancers14143456 · Cited by 60
Mews, P., Zee, B. M., Liu, S., Donahue, G., Garcia, B. A., & Berger, S. L. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00763-14 · Cited by 60
Self-citationLiu, Z., Yao, Y., Kogiso, M., Zheng, B., Deng, L., Qiu, J. J., Dong, S., Lv, H., Gallo, J. M., Li, X., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500660f · Cited by 60
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases
Zurlo, G., Guo, J., Takada, M., Wei, W., & Zhang, Q. H. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.004 · Cited by 62
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Williams, M. J., Singleton, W., Lowis, S. P., Malik, K. T. A., & Kurian, K. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00045 · Cited by 62
Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
Pasquini, L., Napolitano, A., Tagliente, E., Dellepiane, F., Lucignani, M., Vidiri, A., Ranazzi, G., Stoppacciaro, A., Moltoni, G., Nicolai, M., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040290 · Cited by 63
Ogawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 61
Wang, X., Chen, Z., Xu, J., Tang, S., An, N., Jiang, L., Zhang, Y., Zhang, S., Zhang, Q., Shen, Y., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00650-w · Cited by 60
Chatila, W. K., Walch, H. S., Hechtman, J. F., Moyer, S. M., Sgambati, V., Faleck, D. M., Srivastava, A., Tang, L. H., Benhamida, J. K., Ismailgeci, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35592-9 · Cited by 58
Self-citationThe role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
Self-citationIDH mutation is associated with higher risk of malignant transformation in low-grade glioma
Leu, S., von Felten, S., Frank, S., Boulay, J., & Mariani, L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2048-y · Cited by 59
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer
Koschmann, C. J., Núñez, F. J., Mendez, F., Brosnan‐Cashman, J. A., Meeker, A. K., Lowenstein, P. R., & Castro, M. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2301 · Cited by 60
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Dalle, I. A., & Dinardo, C. D. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718777467 · Cited by 60
The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells
Tanabe, A., & Sahara, H. (2020) · Cancers · doi:10.3390/cancers12102780 · Cited by 61
Role of histone modifications in neurogenesis and neurodegenerative disease development
Zhao, A., Xu, W., Han, R., Wei, J., Qi, Y., Wang, M., Li, H., Li, M., & Chi, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102324 · Cited by 65
Venneti, S., Felicella, M. M., Coyne, T. M., Phillips, J. J., Gorovets, D. J., Huse, J. T., Kofler, J., Lü, C., Tihan, T., Sullivan, L. M., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182898113 · Cited by 61
Self-citationReciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer
Yu, X., Ma, R., Wu, Y., Zhai, Y., & Li, S. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00394 · Cited by 64
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 57
SIRT5 Regulates Brown Adipocyte Differentiation and Browning of Subcutaneous White Adipose Tissue
Shuai, L., Zhang, L.-N., Li, B., Tang, C., Wu, L., Li, J., & Li, J. (2019) · Diabetes · doi:10.2337/db18-1103 · Cited by 61
Krautkramer, K. A., Dhillon, R. S., Denu, J. M., & Carey, H. V. (2017) · Translational research · doi:10.1016/j.trsl.2017.08.005 · Cited by 61
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 60
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Stefano, A. L. D., Enciso-Mora, V., Marie, Y., Desestret, V., Labussière, M., Boisselier, B., Mokhtari, K., Idbaïh, A., Hoang‐Xuan, K., Delattre, J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos284 · Cited by 58
Navis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
Matteo, D. A., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A. D., & Sohl, C. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776179 · Cited by 62
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 59
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Le, A., Rajeshkumar, N. V., Maitra, A., & Dang, C. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0041 · Cited by 57
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma
Agnihotri, S., Aldape, K., & Zadeh, G. M. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14505 · Cited by 59
Epigenetics in myelodysplastic syndromes
Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61
Ye, C., Sutter, B. M., Wang, Y., Kuang, Z., Zhao, X., Yu, Y., & Tu, B. P. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.012 · Cited by 56
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
